Gaush Meditech Management
Management criteria checks 3/4
Gaush Meditech's CEO is Xinwei Liu, appointed in Mar 2024, has a tenure of less than a year. total yearly compensation is CN¥1.11M, comprised of 67.6% salary and 32.4% bonuses, including company stock and options. directly owns 0.82% of the company’s shares, worth €1.31M. The average tenure of the management team and the board of directors is 1.8 years and 5.2 years respectively.
Key information
Xinwei Liu
Chief executive officer
CN¥1.1m
Total compensation
| CEO salary percentage | 67.6% |
| CEO tenure | less than a year |
| CEO ownership | 0.8% |
| Management average tenure | 1.8yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥91m |
| Mar 31 2024 | n/a | n/a | CN¥132m |
| Dec 31 2023 | CN¥1m | CN¥748k | CN¥174m |
| Sep 30 2023 | n/a | n/a | -CN¥7m |
| Jun 30 2023 | n/a | n/a | -CN¥187m |
| Mar 31 2023 | n/a | n/a | -CN¥268m |
| Dec 31 2022 | CN¥1m | CN¥726k | -CN¥350m |
| Sep 30 2022 | n/a | n/a | -CN¥278m |
| Jun 30 2022 | n/a | n/a | -CN¥207m |
| Mar 31 2022 | n/a | n/a | -CN¥199m |
| Dec 31 2021 | CN¥1m | CN¥652k | -CN¥190m |
| Dec 31 2020 | CN¥1m | CN¥641k | CN¥99m |
| Dec 31 2019 | CN¥821k | CN¥632k | -CN¥37m |
Compensation vs Market: Xinwei's total compensation ($USD150.99K) is below average for companies of similar size in the German market ($USD837.57K).
Compensation vs Earnings: Xinwei's compensation has been consistent with company performance over the past year.
CEO
Xinwei Liu (42 yo)
less than a year
Tenure
CN¥1,107,000
Compensation
Mr. Xinwei Liu served as Co-Chief Executive Officer of Gaush Meditech Ltd since January 10, 2023 until March 25, 2024 and serves as Chief Executive Officer since March 25, 2024. He is Executive Director of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.1yrs | CN¥1.29m | 42.78% € 68.4m | |
| Executive Director & CEO | less than a year | CN¥1.11m | 0.82% € 1.3m | |
| Honorary President & Executive Director | 2yrs | CN¥815.00k | no data | |
| CFO & Executive Director | 2yrs | CN¥818.00k | no data | |
| Chief Technology Officer | 1.8yrs | CN¥1.96m | no data | |
| Executive Director & Chief Compliance Officer | no data | CN¥1.06m | 0.13% € 207.6k | |
| Joint Company Secretary | 3.2yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
1.8yrs
Average Tenure
51yo
Average Age
Experienced Management: F7Y's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.1yrs | CN¥1.29m | 42.78% € 68.4m | |
| Executive Director & CEO | 5.2yrs | CN¥1.11m | 0.82% € 1.3m | |
| Honorary President & Executive Director | 7.1yrs | CN¥815.00k | no data | |
| CFO & Executive Director | 1.4yrs | CN¥818.00k | no data | |
| Executive Director & Chief Compliance Officer | 7.1yrs | CN¥1.06m | 0.13% € 207.6k | |
| Non-Executive Director | 7.1yrs | no data | no data | |
| Independent Non-Executive Director | 2.2yrs | CN¥243.00k | no data | |
| Independent Non-Executive Director | 2.2yrs | CN¥243.00k | no data | |
| Independent Non-Executive Director | 2.2yrs | CN¥243.00k | no data |
5.2yrs
Average Tenure
57yo
Average Age
Experienced Board: F7Y's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 22:33 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gaush Meditech Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Youjue Hu | Morgan Stanley |